Compounds > busulfan
Page last updated: 2024-10-24

busulfan and Epithelial Ovarian Cancer

busulfan has been researched along with Epithelial Ovarian Cancer in 1 studies

Research Excerpts

ExcerptRelevanceReference
"However, most women (75%) with advanced epithelial ovarian cancer (EOC) will relapse following surgery and chemotherapy."2.53Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer. ( Lane, G; Montes, A; Seshadri, S; Wuntakal, R, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wuntakal, R1
Seshadri, S1
Montes, A1
Lane, G1

Reviews

1 review available for busulfan and Epithelial Ovarian Cancer

ArticleYear
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
    The Cochrane database of systematic reviews, 2016, Jun-29, Issue:6

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Busulfan; Carcinoma, Ovar

2016